Immunovia AB (publ) IMMNOV
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Wait/hold a small watch position until clear volume growth and improved coverage signals emerge.
Q3 demonstrated improved commercial traction and lower burn rate, yet still-low absolute revenue and high dilution support maintaining NEUTRAL.
Sentiment has strengthened due to clear signs of commercial acceleration and reduced losses.
NEUTRAL is the call. Neutral is the market mood. High risk means a lot can go wrong.
Latest change
- 3 Nov 2026 — Results show doubled revenue and lower loss rate following the November 2 release which improved the sentiment trend.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (7) — follow the company freeAbout the company
Immunovia AB (publ) develops and commercializes PancreaSure, a blood test aimed at early detection of pancreatic cancer in high-risk patients. The company is in an early U.S. commercialization phase with very low revenues and continued cash burn. Key value drivers are reimbursement/coverage, state-by-state regulatory rollout, and clinical utility evidence.
Bull case
Confirmed Medicare reimbursement could rapidly expand sales from a low valuation.
Bear case
Absence of Medicare news combined with still-low revenue risks increasing financing concerns.
Why this signal
Q3 demonstrated improved commercial traction and lower burn rate, yet still-low absolute revenue and high dilution support maintaining NEUTRAL.
Recent news
The Q3 report released on 2 November showed record PancreaSure sales, nine new centers and lower cash burn. The stock rebounded sharply on the news after the prior week's drop.